Assembly Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	74.85	72.3	28.52	7.16	-	6.25
Revenue Growth	125.12%	153.52%	298.16%	-	-	-92.09%
Cost of Revenue	63.65	64.81	55.93	48.9	69.08	70.15
Gross Profit	11.19	7.49	-27.41	-41.74	-69.08	-63.9
Selling, General & Admin	19.99	19.61	18.01	22.91	23.93	28.5
Operating Expenses	19.99	19.61	18.01	22.91	23.93	28.5
Operating Income	-8.8	-12.12	-45.42	-64.65	-93.01	-92.4
Interest & Investment Income	8.76	6	5.57	3.45	1.02	0.3
EBT Excluding Unusual Items	-0.04	-6.12	-39.85	-61.2	-91.99	-92.1
Merger & Restructuring Charges	-	-	-	-	-1.1	1.35
Impairment of Goodwill	-	-	-	-	-	-12.6
Asset Writedown	-	-	-	-	-	-0.04
Pretax Income	-0.04	-6.12	-39.85	-61.2	-93.09	-132.39
Income Tax Expense	-	-	0.33	0.03	-	-2.53
Net Income	-0.04	-6.12	-40.18	-61.23	-93.09	-129.86
Net Income to Common	-0.04	-6.12	-40.18	-61.23	-93.09	-129.86
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	16	11	6	5	4	4
Shares Outstanding (Diluted)	16	11	6	5	4	4
Shares Change	133.27%	86.71%	31.18%	13.47%	11.85%	22.17%
EPS (Basic)	-0.00	-0.55	-6.69	-13.38	-23.08	-36.00
EPS (Diluted)	-0.00	-0.55	-6.69	-13.38	-23.08	-36.00
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-38.57	-41.16	-51.15	22.49	-84.57	-96.49
Free Cash Flow Per Share	-2.36	-3.67	-8.52	4.91	-20.96	-26.75
Gross Margin	14.95%	10.36%	-96.12%	-	-	-
Operating Margin	-11.76%	-16.76%	-159.26%	-902.50%	-	-1477.42%
Profit Margin	-0.06%	-8.47%	-140.87%	-854.78%	-	-2076.35%
Free Cash Flow Margin	-51.53%	-56.93%	-179.33%	313.95%	-	-1542.88%
EBITDA	-8.69	-11.99	-45.29	-64.2	-92.52	-91.93
EBITDA Margin	-11.61%	-16.58%	-158.80%	-	-	-
D&A For EBITDA	0.11	0.13	0.13	0.45	0.5	0.47
EBIT	-8.8	-12.12	-45.42	-64.65	-93.01	-92.4
EBIT Margin	-11.76%	-16.76%	-159.26%	-	-	-

SEC Filings: 10-K · 10-Q